Boston Scientific (BSX) Short term Debt (2016 - 2025)
Boston Scientific (BSX) has disclosed Short term Debt for 17 consecutive years, with $299.0 million as the latest value for Q4 2025.
- Quarterly Short term Debt fell 83.18% to $299.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $299.0 million through Dec 2025, down 83.18% year-over-year, with the annual reading at $299.0 million for FY2025, 83.18% down from the prior year.
- Short term Debt hit $299.0 million in Q4 2025 for Boston Scientific, down from $483.0 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $1.8 billion in Q4 2024 to a low of $13.0 million in Q1 2021.
- Historically, Short term Debt has averaged $574.6 million across 5 years, with a median of $481.5 million in 2025.
- Biggest five-year swings in Short term Debt: tumbled 92.34% in 2022 and later skyrocketed 2555.0% in 2023.
- Year by year, Short term Debt stood at $261.0 million in 2021, then crashed by 92.34% to $20.0 million in 2022, then surged by 2555.0% to $531.0 million in 2023, then skyrocketed by 234.84% to $1.8 billion in 2024, then crashed by 83.18% to $299.0 million in 2025.
- Business Quant data shows Short term Debt for BSX at $299.0 million in Q4 2025, $483.0 million in Q3 2025, and $480.0 million in Q2 2025.